Dolutegravir Sodium Tablets Approved for Market Launch! Domestically-Produced Anti-HIV Treatment Adds Another Essential Drug

Kua Technology, March 15 — Today, Aidi Pharmaceutical announced that its Dotravirine Sodium Tablets have received approval from the National Medical Products Administration for market listing.

The product is registered as a chemical drug in Class 4, and approval is considered equivalent to the approval of generic drug quality and efficacy consistency evaluation.

According to reports, Dotravirine Sodium Tablets are HIV-1 integrase strand transfer inhibitors and are currently a first-line core treatment drug in the global HIV infection treatment field.

The approved indication is in combination with other antiretroviral drugs for the treatment of HIV-infected adults and children aged 12 and above.

The original drug has been consistently recommended as one of the preferred first-line treatment options for adult and adolescent HIV patients by major domestic and international treatment guidelines, including China’s AIDS Diagnosis and Treatment Guidelines, the US DHHS guidelines, and the European EACS guidelines.

It is understood that Aidi Pharmaceutical is a leading enterprise in China’s HIV prevention and treatment field. The company previously launched Ainomitre (Fubangde), and Dotravirine Sodium Tablets will complement its portfolio, supporting China’s AIDS prevention and control efforts.